Maravai LifeSciences Holdings, Inc. (MRVI) stock
MRVINasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30170% above fair value
$7.40−0.14 (-1.86%)
Close on Nov 16, 2026Market cap $1.92BP/E –Yield –
Maravai LifeSciences gross margin
Gross margin is gross profit as a percentage of revenue.
Maravai LifeSciences's gross margin for the twelve months ending Jun 30, 2026 was 34.9%. For fiscal 2025 it was 18.3%, against 41.8% the year before. The highest annual figure on record is 82.4% in fiscal 2021.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 18.3% | −23.5 |
| FY2024 | Dec 31, 2024 | 41.8% | −6.7 |
| FY2023 | Dec 31, 2023 | 48.5% | −32.3 |
| FY2022 | Dec 31, 2022 | 80.9% | −1.5 |
| FY2021 | Dec 31, 2021 | 82.4% | +10.4 |
| FY2020 | Dec 31, 2020 | 72.0% | +18.7 |
| FY2019 | Dec 31, 2019 | 53.3% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 40.1% | +23.8 |
| Q1 FY2026 | Mar 31, 2026 | 51.2% | +34.7 |
| Q4 FY2025 | Dec 31, 2025 | 25.8% | −8.5 |
| Q3 FY2025 | Sep 30, 2025 | 13.6% | −33.1 |
| Q2 FY2025 | Jun 30, 2025 | 16.4% | −28.0 |
| Q1 FY2025 | Mar 31, 2025 | 16.5% | −23.8 |
| Q4 FY2024 | Dec 31, 2024 | 34.3% | −18.4 |
| Q3 FY2024 | Sep 30, 2024 | 46.7% | +1.6 |
| Q2 FY2024 | Jun 30, 2024 | 44.4% | +7.2 |
| Q1 FY2024 | Mar 31, 2024 | 40.3% | −17.1 |
| Q4 FY2023 | Dec 31, 2023 | 52.6% | −21.3 |
| Q3 FY2023 | Sep 30, 2023 | 45.1% | −34.9 |
| Q2 FY2023 | Jun 30, 2023 | 37.2% | −47.3 |
| Q1 FY2023 | Mar 31, 2023 | 57.4% | −26.2 |
| Q4 FY2022 | Dec 31, 2022 | 74.0% | −8.9 |
| Q3 FY2022 | Sep 30, 2022 | 80.0% | −4.2 |
| Q2 FY2022 | Jun 30, 2022 | 84.6% | +1.9 |
| Q1 FY2022 | Mar 31, 2022 | 83.6% | +4.8 |
| Q4 FY2021 | Dec 31, 2021 | 82.9% | +6.7 |
| Q3 FY2021 | Sep 30, 2021 | 84.3% | +6.8 |
| Q2 FY2021 | Jun 30, 2021 | 82.6% | +27.8 |
| Q1 FY2021 | Mar 31, 2021 | 78.8% | +8.8 |
| Q4 FY2020 | Dec 31, 2020 | 76.2% | – |
| Q3 FY2020 | Sep 30, 2020 | 77.5% | – |
| Q2 FY2020 | Jun 30, 2020 | 54.8% | – |
| Q1 FY2020 | Mar 31, 2020 | 70.0% | – |
See a number that looks wrong?